⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899759 | 0.74 | ALDH1A1 (0.47) | — | |
| SCHEMBL14842937 | 0.74 | ALDH1A1 (0.47) | — | |
| SCHEMBL1289911 | 0.74 | — | — | |
| SCHEMBL11060397 | 0.73 | — | — | |
| SCHEMBL561117 | 0.71 | — | — | |
| SCHEMBL4450142 | 0.71 | — | — | |
| SCHEMBL31094446 | 0.71 | — | — | |
| SCHEMBL1663683 | 0.69 | — | — | |
| SCHEMBL22988 | 0.69 | — | — | |
| SCHEMBL294315 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| CN-110114358-A | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2019-08-09 | — | — | CN | disclosed |
| EP-3226885-A2 | INTERMEDIATES AND PROCESSES TO PREPARE MICAFUNGIN | Alaparthi, Lakshmi Prasad (IN) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016056023-A2 | INTERMEDIATES AND PROCESSES TO PREPARE MICAFUNGIN | ALAPARTHI LAKSHMI PRASAD (IN) | 2016-04-14 | — | — | WO | disclosed |
| US-20060264494-A1 | Heterocyclic amide derivatives which process glycogen phorylase inhibitory activity | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| US-20060199966-A1 | Indol-2-amides as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2006-09-07 | — | — | US | disclosed |
| EP-1660448-A1 | INDOL-2-AMIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1656136-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005018637-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019172-A1 | INDOL-2-AMIDES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |